At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.
From academia to innovation
Founded on groundbreaking research from UC Berkeley and UC San Francisco, Nurix started as an E3 ligase-centric company. Our deep understanding of the E3 ligase biochemistry, structure, and biological activity laid the foundation for our innovative approach to drug discovery and development.
At the heart of our innovation is our proprietary DEL-AI discovery engine. This powerful engine integrates our in-house DNA Encoded Libraries (DEL), expansive collection of ligase binders, and automated chemistry and direct-to-biology capabilities, with novel insights from the application of machine learning leveraged across the platform. DEL-AI is the cornerstone of our ability to develop truly novel drugs in parallel against a broad set of targets, giving us a formidable advantage in translating the science of degradation into clinical advances for patients.
It’s essential that we use the intelligence, innovation and grit of scientific endeavors to improve the world. One way we can do that is by inventing new therapies that could help address currently untreatable diseases or disease processes.
Gwenn M. Hansen, Ph.D.
Chief Scientific Officer
Expanding therapeutic possibilities
From the beginning, we have recognized the immense potential of targeted protein degradation to address not just cancer and autoimmune disease, our current areas of focus, but a vast spectrum of diseases. We are steadfast in our pursuit to investigate the promise of degrader-based medicines.